[Intra-arterial cellular immunochemotherapy for unresectable pancreatic cancer with liver metastasis].
OBJECTIVE
To date, no treatment has had a significant impact on pancreatic cancer with liver metastasis. We performed locoregional cellular immunochemotherapy for unresectable pancreatic cancer with liver metastasis.


METHODS
A 71-year-old man was diagnosed for unresectable stage IVb pancreatic cancer. This patient was given intra-arterial infusion of gemcitabine (GEM) 400 mg/body and intravenous infusion GEM 600 mg/body, simultaneously. The day after GEM infusion, he was given intra-arterial autologous tumor cell activated T lymphocytes (AuTL).


RESULTS
Tumor markers, such as CEA and CA19-9, had decreased a little. Primary tumor and metastatic liver tumor were reduced, but he died due to intra-abdominal dissemination within 5 months after diagnosis of unresectable pancreatic cancer.


CONCLUSIONS
Reduced primary pancreatic tumor and metastatic liver tumor was obtained by locoregional cellular immunochemotherapy. But we could not control intra-abdominal dissemination. In conclusion, we suggest that intra-abdominal AuLT infusion in combination with intra-arterial AuLT infusion may be advisable to patients for unresectable pancreatic carcinoma with intra-abdominal dissemination.
Horiuchi
Hiroyuki
H
Dept. of Surgery, Kurume University, School of Medicine.
Toh
Uhi
U
Uchida
Shinji
S
Hayashi
Katsumi
K
Kinoshita
Hisafumi
H
Yamana
Hideaki
H
Aoyagi
Shigeaki
S
Shirouzu
Kazuo
K
Koganemaru
Masamichi
M
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D014408:Biomarkers, Tumor; D001804:Blood Transfusion, Autologous; D003841:Deoxycytidine / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D006801:Humans; D007261:Infusions, Intra-Arterial; D007262:Infusions, Intravenous; D007694:Killer Cells, Natural / Q000276:immunology / Q000637:transplantation*; D008113:Liver Neoplasms / Q000556:secondary*; D008297:Male; D010190:Pancreatic Neoplasms / Q000473:pathology* / Q000628:therapy*; D016896:Treatment Outcome; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D014408:Biomarkers, Tumor; D003841:Deoxycytidine; D000093542:Gemcitabine